loading...| Preferred Name |
Rosuvastatin |
|
| Synonyms |
Rosuvastatin ROSUVASTATIN |
|
| Definitions |
A statin with antilipidemic and potential antineoplastic activities. Rosuvastatin selectively and competitively binds to and inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme which catalyzes the conversion of HMG-CoA to mevalonate, a precursor of cholesterol. This leads to a decrease in hepatic cholesterol levels and increase in uptake of LDL cholesterol. In addition, rosuvastatin, like other statins, exhibits pro-apoptotic, growth inhibitory, and pro-differentiation activities in a variety of tumor cell types; these antineoplastic activities may be due, in part, to inhibition of the isoprenylation of Ras and Rho GTPases and related signaling cascades. |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C66523 |
|
| CAS_Registry |
287714-41-4 |
|
| CHEBI_ID |
CHEBI:38545 |
|
| Chemical_Formula |
C22H28FN3O6S |
|
| code |
C66523 |
|
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C173381 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C173383 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784 |
|
| Contributing_Source |
CTRP FDA GDC |
|
| DEFINITION |
A statin with antilipidemic and potential antineoplastic activities. Rosuvastatin selectively and competitively binds to and inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme which catalyzes the conversion of HMG-CoA to mevalonate, a precursor of cholesterol. This leads to a decrease in hepatic cholesterol levels and increase in uptake of LDL cholesterol. In addition, rosuvastatin, like other statins, exhibits pro-apoptotic, growth inhibitory, and pro-differentiation activities in a variety of tumor cell types; these antineoplastic activities may be due, in part, to inhibition of the isoprenylation of Ras and Rho GTPases and related signaling cascades. |
|
| Display_Name |
Rosuvastatin |
|
| FDA_UNII_Code |
413KH5ZJ73 |
|
| FULL_SYN |
Rosuvastatin ROSUVASTATIN |
|
| Has_Salt_Form | ||
| Has_Target | ||
| Is_Value_For_GDC_Property | ||
| label |
Rosuvastatin |
|
| Legacy Concept Name |
Rosuvastatin |
|
| Maps_To |
Rosuvastatin |
|
| NCI_Drug_Dictionary_ID |
654583 |
|
| PDQ_Closed_Trial_Search_ID |
654583 |
|
| PDQ_Open_Trial_Search_ID |
654583 |
|
| Preferred_Name |
Rosuvastatin |
|
| prefixIRI |
Thesaurus:C66523 |
|
| Semantic_Type |
Pharmacologic Substance |
|
| UMLS_CUI |
C0965129 |
|
| subClassOf |